Pelvic Organ Prolapse Pelvic Floor Reconstruction Market - Global Forecast to 2030
商品番号 : SMB-89314
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 332 |
| 図表数 | 387 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
骨盤臓器脱の治療と管理 / 骨盤臓器脱市場 – 製品（合成メッシュ、縫合糸、ペッサリー、ロボットシステム）、治療（外科手術、PFMT）、用途（膀胱瘤、子宮脱）、エンドユーザー（病院、ASC）、地域別 – 2030年までの世界予測
世界のPOP治療および管理/骨盤臓器脱市場は、予測期間中に6.6%のCAGRで成長し、2025年の7億7,000万米ドルから2030年には10億6,000万米ドルに達すると予測されています。
骨盤臓器脱の世界的な有病率の高さ、高齢女性人口の増加、認知度の高まりと早期診断、そして低侵襲手術やロボット手術技術の進歩により、市場は高い成長が見込まれています。膣メッシュに伴う合併症やリコール、発展途上国におけるアクセスの制限や価格の高騰、社会的偏見による診断不足、そしてPOP製品のリスクは、市場の成長を抑制する可能性があります。
本レポートは、骨盤臓器脱の治療と管理／骨盤臓器脱市場を、製品、治療、用途、エンドユーザー、地域の観点から分析しています。また、市場の成長に影響を与える要因（推進要因、制約要因、機会、課題など）を分析するとともに、市場リーダー企業の競争環境の詳細も提供しています。さらに、ミクロ市場を個々の成長傾向の観点から分析しています。さらに、5つの主要地域（および各地域における各国）における市場セグメントの収益予測も提供しています。
本レポートは、既存企業だけでなく新規参入企業や小規模企業も市場の動向を把握し、より大きな市場シェアを獲得することを可能にします。本レポートを購入した企業は、以下に示す戦略のいずれか、または組み合わせて活用することで、市場プレゼンスを強化できます。
Report Description
The global POP Treatment and Management / Pelvic Organ Prolapse market is projected to reach USD 1.06 billion by 2030 from USD 0.77 billion in 2025, at a CAGR of 6.6% during the forecast period.
The market is expected to witness high growth due to the high global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques. Complications and recalls associated with vaginal mesh, limited access and affordability in developing markets, underdiagnosis due to social stigma, and the risk of POP products are likely to restrain market growth.
“The hospitals segment of the POP Treatment and Management / Pelvic Organ Prolapse market, by end user, is expected to hold the largest position during the forecast period.”
Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others. In 2024, hospitals and clinics accounted for the largest share of the market. Hospitals benefit from centralized procurement systems, allowing for efficient integration of new POP technologies. Their access to government or institutional funding also facilitates the acquisition of expensive devices, such as robotic surgical systems, which may not be feasible in smaller outpatient facilities. Furthermore, hospitals are often the only facilities equipped to manage intraoperative complications, complex reconstructions, and comorbid conditions in elderly patients—ensuring their continued dominance in the pelvic organ prolapse treatment landscape.
“The surgical segment accounted for the larger market share in the POP Treatment and Management / Pelvic Organ Prolapse market.”
The POP Treatment and Management / Pelvic Organ Prolapse market is segmented into surgical and non-surgical. The surgical segment accounted for the larger share of the market in 2024. Surgical intervention is often preferred in cases involving multiple-compartment prolapses or associated conditions like stress urinary incontinence. Moreover, with the growing availability of minimally invasive and robotic-assisted methods, surgical options now offer quicker recovery and reduced postoperative complications, making them more acceptable to both patients and clinicians. Continuous innovation in surgical meshes, biologic grafts, and energy-assisted dissection tools further enhances procedural outcomes. Importantly, surgical treatments are backed by strong clinical guidelines and are often the first-line recommendation in moderate to severe POP, reinforcing their dominant position in the market.
“Asia Pacific is the fastest-growing market for POP Treatment and Management / Pelvic Organ Prolapse.”
The global POP Treatment and Management / Pelvic Organ Prolapse market is segmented into five segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is experiencing rapid population aging, especially in countries like China and Japan, leading to a rising incidence of pelvic organ prolapse disorders among elderly women. Increasing awareness of women’s health and growing acceptance of pelvic floor treatments are driving higher diagnosis and treatment rates. Governments across the region are investing in healthcare infrastructure, expanding access to surgical facilities, and supporting the adoption of advanced medical technologies, including robotic-assisted procedures. The rise of medical tourism in countries such as India and South Korea further fuels market growth, offering high-quality care at lower costs. While access disparities and a shortage of trained specialists still exist in rural areas, ongoing investments in healthcare training, digital health platforms, and public awareness campaigns are helping to close these gaps, positioning Asia Pacific as the fastest-growing regional market.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
- By Designation: C Level: 27%, Director Level: 18%, and Others: 55%
- By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%
Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the POP Treatment and Management / Pelvic Organ Prolapse market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), and Johnson & Johnson (US).
Research Coverage
This report studies the POP Treatment and Management / Pelvic Organ Prolapse market based on product, treatment, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them to garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.
This report provides insights into the following pointers:
Analysis of key drivers (High global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques), restraints (complications and recalls associated with vaginal mesh, limited access and affordability in developing market, and underdiagnosis due to social stigma), opportunities (growth opportunities in emerging economies, development of bioengineered and absorbable mesh and digital health and pelvic floor therapy devices), and challenges (inconsistent clinical guidelines and treatment standards, and high recurrence and reoperation rates)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the POP Treatment and Management / Pelvic Organ Prolapse market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the POP Treatment and Management / Pelvic Organ Prolapse market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the POP Treatment and Management / Pelvic Organ Prolapse market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 33
1.4 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.1.1 List of secondary sources 35
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 List of primary sources 36
2.1.2.2 Key data from primary sources 37
2.1.2.3 Breakdown of primary interviews 38
2.1.2.4 Insights from industry experts 38
2.2 MARKET SIZE ESTIMATION 39
2.2.1 BOTTOM-UP APPROACH 39
2.2.1.1 Approach 1: Revenue estimation of key players 39
2.2.1.2 Approach 2: Study of annual reports and investor presentations 39
2.2.1.3 Approach 3: Primary interviews 40
2.2.1.4 Growth forecast 40
2.2.1.5 CAGR projections 40
2.2.2 TOP-DOWN APPROACH 41
2.3 DATA TRIANGULATION 42
2.4 RESEARCH ASSUMPTIONS 43
2.4.1 STUDY-RELATED ASSUMPTIONS 43
2.4.2 PARAMETRIC ASSUMPTIONS 43
2.4.3 GROWTH RATE ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 44
2.6 RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
4 PREMIUM INSIGHTS 51
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PELVIC ORGAN PROLAPSE/
PELVIC FLOOR RECONSTRUCTION MARKET 51
4.2 ASIA PACIFIC PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER AND COUNTRY 52
4.3 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION 53
4.4 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Global prevalence of pelvic organ prolapse 56
5.2.1.2 Rise in female geriatric population 56
5.2.1.3 Improved awareness and early diagnosis 57
5.2.1.4 Advancements in robotic surgical techniques 57
5.2.2 RESTRAINTS 58
5.2.2.1 Complications and recalls associated with transvaginal synthetic mesh 58
5.2.2.2 Limited access in emerging economies 58
5.2.2.3 Underdiagnosis due to social stigma 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Increased investments in pelvic organ prolapse care from emerging economies 59
5.2.3.2 Rapid development of bioengineered and absorbable mesh 59
5.2.3.3 Advent of digital pelvic health solutions 60
5.2.4 CHALLENGES 60
5.2.4.1 Inconsistent clinical guidelines and treatment standards 60
5.2.4.2 High recurrence and reoperation rates 60
5.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 61
5.4 PRICING ANALYSIS 61
5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT 61
5.4.2 AVERAGE SELLING PRICE TREND, BY TREATMENT AND KEY PLAYER 62
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 63
5.5 VALUE CHAIN ANALYSIS 63
5.6 SUPPLY CHAIN ANALYSIS 65
5.7 ECOSYSTEM ANALYSIS 66
5.8 INVESTMENT AND FUNDING SCENARIO 67
5.9 TECHNOLOGY ANALYSIS 68
5.9.1 KEY TECHNOLOGIES 68
5.9.1.1 Pelvic mesh implants 68
5.9.1.2 Vaginal pessaries 69
5.9.2 COMPLEMENTARY TECHNOLOGIES 69
5.9.2.1 Wearable and app-based pelvic therapy devices 69
5.9.3 ADJACENT TECHNOLOGIES 69
5.9.3.1 Urinary incontinence devices 69
5.10 PATENT ANALYSIS 70
5.11 TRADE ANALYSIS 72
5.11.1 IMPORT SCENARIO (HS CODE 901890) 72
5.11.2 EXPORT SCENARIO (HS CODE 901890) 73
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 73
5.13 CASE STUDY ANALYSIS 74
5.13.1 NEGLECTED PESSARY IN PATIENT WITH PELVIC ORGAN PROLAPSE 74
5.13.2 SUCCESSFUL USE OF PESSARY FOR UTERINE PROLAPSE AFTER PELVIC TRAUMA IN YOUNG, NULLIPAROUS FEMALE 74
5.13.3 ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE 75
5.14 REGULATORY LANDSCAPE 75
5.14.1 REGULATORY ANALYSIS 75
5.14.1.1 North America 75
5.14.1.1.1 US 75
5.14.1.1.2 Canada 75
5.14.1.2 Europe 76
5.14.1.2.1 Germany 76
5.14.1.2.2 UK 76
5.14.1.2.3 France 76
5.14.1.3 Asia Pacific 77
5.14.1.3.1 China 77
5.14.1.3.2 Japan 77
5.14.1.3.3 India 77
5.14.1.4 Latin America 78
5.14.1.5 Middle East 78
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.15 PORTER’S FIVE FORCES ANALYSIS 80
5.15.1 BARGAINING POWER OF SUPPLIERS 81
5.15.2 BARGAINING POWER OF BUYERS 81
5.15.3 THREAT FROM NEW ENTRANTS 81
5.15.4 THREAT FROM SUBSTITUTES 81
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 82
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
5.16.2 BUYING CRITERIA 83
5.17 IMPACT OF AI 84
5.17.1 INTRODUCTION 84
5.17.2 POTENTIAL OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 84
5.17.3 KEY COMPANIES IMPLEMENTING AI 85
5.17.4 FUTURE OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 86
5.18 US 2025 TARIFF 86
5.18.1 INTRODUCTION 86
5.18.2 KEY TARIFF RATES 87
5.18.3 PRICE IMPACT ANALYSIS 88
5.18.4 IMPACT ON COUNTRY/REGION 88
5.18.4.1 North America 88
5.18.4.2 Europe 88
5.18.4.3 Asia Pacific 88
5.18.5 IMPACT ON END-USE INDUSTRIES 89
5.18.5.1 Hospitals 89
6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT 90
6.1 INTRODUCTION 91
6.2 SYNTHETIC MESH 91
6.2.1 ADOPTION OF ADVANCED, PATIENT-FOCUSED MESH TECHNOLOGIES 91
6.3 BIOLOGICAL GRAFTS 95
6.3.1 SHIFT TOWARD BIOCOMPATIBLE ALTERNATIVES 95
6.4 SUTURES 98
6.4.1 NEED FOR PRECISION IN PELVIC REPAIRS WITH ABSORBABLE AND ANTIBACTERIAL PRODUCTS 98
6.5 VAGINAL PESSARIES 102
6.5.1 INTRODUCTION OF CUSTOM-FIT, HOME-USE PESSARY SOLUTIONS 102
6.6 PELVIC FLOOR THERAPY DEVICES 106
6.6.1 PATIENT PREFERENCE FOR MANAGING PELVIC FLOOR DISORDERS INDEPENDENTLY 106
6.7 ROBOTIC SURGERY SYSTEMS 109
6.7.1 ELEVATED DEMAND FOR MINIMALLY INVASIVE SOLUTIONS IN COMPLEX PELVIC REPAIRS 109
6.8 DIAGNOSTIC & ASSESSMENT TOOLS 112
6.8.1 ACCURATE DETECTION WITH ADVANCED IMAGING AND SMART DEVICES 112
7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT 116
7.1 INTRODUCTION 117
7.2 SURGICAL 117
7.2.1 COLPOCLEISIS 121
7.2.1.1 Large-scale adoption among older women 121
7.2.2 COLPORRHAPY 124
7.2.2.1 Increased preference for foundational repair techniques 124
7.2.3 SACROCOLPOPEXY 127
7.2.3.1 Reduced postoperative discomfort and quicker recovery 127
7.2.4 SACROHYSTEROPEXY 130
7.2.4.1 Rise in demand for uterine-preserving options for prolapse repair 130
7.2.5 UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION 133
7.2.5.1 Surge in native tissue repairs without mesh-based interventions 133
7.3 NON-SURGICAL 136
7.3.1 VAGINAL PESSARY MANAGEMENT 139
7.3.1.1 Emphasis on early intervention 139
7.3.2 PELVIC FLOOR MUSCLE THERAPY 142
7.3.2.1 Extensive use in early-stage prolapse and postpartum women 142
8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION 145
8.1 INTRODUCTION 146
8.2 CYSTOCELE 146
8.2.1 WEAKENED PELVIC FLOOR MUSCLES PROMPT DEVELOPMENT 146
8.3 URETHROCELE 149
8.3.1 CHRONIC INCREASE IN INTRA-ABDOMINAL PRESSURE 149
8.4 ENTEROCELE 152
8.4.1 SURGE IN APICAL VAGINAL SUPPORT DEFICIENCY 152
8.5 UTERINE PROLAPSE 155
8.5.1 GROWTH IN PROLAPSE BURDEN 155
8.6 RECTOCELE 158
8.6.1 PREVALENCE OF RECTOVAGINAL SEPTUM DEFICIENCY 158
9 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER 162
9.1 INTRODUCTION 163
9.2 HOSPITALS 163
9.2.1 HIGH PATIENT INFLOW AND WIDESPREAD AVAILABILITY OF REIMBURSEMENTS 163
9.3 SPECIALTY CLINICS 167
9.3.1 HEIGHTENED DEMAND FOR TAILORED, NON-INVASIVE, AND ACCESSIBLE CARE 167
9.4 AMBULATORY SURGERY CENTERS 170
9.4.1 COST ADVANTAGES AND FAVORABLE CLINICAL OUTCOMES 170
9.5 OTHER END USERS 173
10 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY REGION 177
10.1 INTRODUCTION 178
10.2 NORTH AMERICA 178
10.2.1 MACROECONOMIC OUTLOOK 179
10.2.2 US 184
10.2.2.1 Rise in female geriatric population to drive market 184
10.2.3 CANADA 188
10.2.3.1 High symptom prevalence and demographic trends to drive market 188
10.3 EUROPE 191
10.3.1 MACROECONOMIC OUTLOOK 191
10.3.2 GERMANY 196
10.3.2.1 Advanced surgical innovations to drive market 196
10.3.3 FRANCE 199
10.3.3.1 Increased clinical focus on pelvic floor disorders and pelvic organ prolapse to drive market 199
10.3.4 UK 203
10.3.4.1 Women’s health policy initiatives to drive market 203
10.3.5 ITALY 207
10.3.5.1 Demographic shifts to drive market 207
10.3.6 SPAIN 211
10.3.6.1 Rising popularity of non-surgical interventions to drive market 211
10.3.7 REST OF EUROPE 214
10.4 ASIA PACIFIC 218
10.4.1 MACROECONOMIC OUTLOOK 218
10.4.2 CHINA 223
10.4.2.1 Growing incidence of pelvic organ prolapse to drive market 223
10.4.3 JAPAN 227
10.4.3.1 Evolving healthcare delivery and infrastructure landscape to drive market 227
10.4.4 INDIA 231
10.4.4.1 Booming medical tourism to drive market 231
10.4.5 AUSTRALIA 235
10.4.5.1 Rapid growth of medical manufacturing companies to drive market 235
10.4.6 SOUTH KOREA 239
10.4.6.1 Surge in healthcare spending to drive market 239
10.4.7 REST OF ASIA PACIFIC 242
10.5 LATIN AMERICA 246
10.5.1 MACROECONOMIC OUTLOOK 246
10.5.2 BRAZIL 250
10.5.2.1 Improving healthcare infrastructure to drive market 250
10.5.3 MEXICO 254
10.5.3.1 Expanding healthcare awareness and services to drive market 254
10.5.4 REST OF LATIN AMERICA 257
10.6 MIDDLE EAST & AFRICA 261
10.6.1 MACROECONOMIC OUTLOOK 261
11 COMPETITIVE LANDSCAPE 265
11.1 INTRODUCTION 265
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 265
11.3 REVENUE ANALYSIS, 2022–2024 267
11.4 MARKET SHARE ANALYSIS, 2024 267
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 270
11.5.1 STARS 270
11.5.2 EMERGING LEADERS 270
11.5.3 PERVASIVE PLAYERS 270
11.5.4 PARTICIPANTS 270
11.5.5 COMPANY FOOTPRINT 272
11.5.5.1 Company footprint 272
11.5.5.2 Region footprint 272
11.5.5.3 Product footprint 273
11.5.5.4 Treatment footprint 274
11.5.5.5 Application footprint 274
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 275
11.6.1 PROGRESSIVE COMPANIES 275
11.6.2 RESPONSIVE COMPANIES 275
11.6.3 DYNAMIC COMPANIES 275
11.6.4 STARTING BLOCKS 275
11.6.5 COMPETITIVE BENCHMARKING 277
11.6.5.1 List of start-ups/SMEs 277
11.6.5.2 Competitive benchmarking of start-ups/SMEs 278
11.7 COMPANY VALUATION AND FINANCIAL METRICS 279
11.8 BRAND/PRODUCT COMPARISON 280
11.9 COMPETITIVE SCENARIO 281
11.9.1 PRODUCT LAUNCHES/APPROVALS 281
11.9.2 DEALS 282
11.9.3 OTHER DEVELOPMENTS 283
12 COMPANY PROFILES 284
12.1 KEY PLAYERS 284
12.1.1 BOSTON SCIENTIFIC CORPORATION 284
12.1.1.1 Business overview 284
12.1.1.2 Products offered 285
12.1.1.3 Recent developments 286
12.1.1.3.1 Deals 286
12.1.1.4 MnM view 286
12.1.1.4.1 Right to win 286
12.1.1.4.2 Strategic choices 286
12.1.1.4.3 Weaknesses and competitive threats 286
12.1.2 COLOPLAST GROUP 287
12.1.2.1 Business overview 287
12.1.2.2 Products offered 289
12.1.2.3 MnM view 289
12.1.2.3.1 Right to win 289
12.1.2.3.2 Strategic choices 289
12.1.2.3.3 Weaknesses and competitive threats 289
12.1.3 INTUITIVE SURGICAL OPERATIONS, INC. 290
12.1.3.1 Business overview 290
12.1.3.2 Products offered 291
12.1.3.3 Recent developments 292
12.1.3.3.1 Product launches/approvals 292
12.1.3.4 MnM view 292
12.1.3.4.1 Right to win 292
12.1.3.4.2 Strategic choices 292
12.1.3.4.3 Weaknesses and competitive threats 292
12.1.4 COOPERCOMPANIES 293
12.1.4.1 Business overview 293
12.1.4.2 Products offered 294
12.1.4.3 Recent developments 295
12.1.4.3.1 Deals 295
12.1.4.4 MnM view 295
12.1.4.4.1 Right to win 295
12.1.4.4.2 Strategic choices 295
12.1.4.4.3 Weaknesses and competitive threats 295
12.1.5 JOHNSON & JOHNSON 296
12.1.5.1 Business overview 296
12.1.5.2 Products offered 297
12.1.5.3 Recent developments 298
12.1.5.3.1 Product launches/approvals 298
12.1.5.3.2 Deals 298
12.1.5.3.3 Other developments 298
12.1.5.4 MnM view 299
12.1.5.4.1 Right to win 299
12.1.5.4.2 Strategic choices 299
12.1.5.4.3 Weaknesses and competitive threats 299
12.1.6 GE HEALTHCARE 300
12.1.6.1 Business overview 300
12.1.6.2 Products offered 301
12.1.6.3 Recent developments 302
12.1.6.3.1 Product launches/approvals 302
12.1.6.3.2 Deals 302
12.1.6.3.3 Other developments 302
12.1.7 INTEGRA LIFESCIENCES CORPORATION 303
12.1.7.1 Business overview 303
12.1.7.2 Products offered 304
12.1.8 B. BRAUN SE 305
12.1.8.1 Business overview 305
12.1.8.2 Products offered 306
12.1.8.3 Recent developments 307
12.1.8.3.1 Deals 307
12.1.9 PFM MEDICAL GMBH 308
12.1.9.1 Business overview 308
12.1.9.2 Products offered 308
12.1.10 CALDERA MEDICAL 309
12.1.10.1 Business overview 309
12.1.10.2 Products offered 309
12.1.10.3 Recent developments 310
12.1.10.3.1 Deals 310
12.2 OTHER PLAYERS 311
12.2.1 KEGEL8 311
12.2.2 MEDGYN PRODUCTS INC. 312
12.2.3 BETATECH MEDICAL 313
12.2.4 FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH 314
12.2.5 BIOTEQUE AMERICA INC. 315
12.2.6 PERSONAL MEDICAL CORP. 316
12.2.7 DIPROMED SRL 316
12.2.8 A.M.I. GMBH 317
12.2.9 BRAY GROUP 318
12.2.10 DIGITIMER LTD 319
12.2.11 MEDESIGN I.C. GMBH 320
12.2.12 DR. ARABIN GMBH & CO. KG 321
12.2.13 FOR.ME.SA. 322
12.2.14 COSM MEDICAL 322
12.2.15 WILLOW INNOVATIONS, INC. 323
13 APPENDIX 324
13.1 DISCUSSION GUIDE 324
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 328
13.3 CUSTOMIZATION OPTIONS 330
13.4 RELATED REPORTS 330
13.5 AUTHOR DETAILS 331
LIST OF TABLES
TABLE 1 POPULATION OF FEMALES AGED 50 AND ABOVE, 2024 56
TABLE 2 AVERAGE SELLING PRICING TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY TYPE, 2023–2025 62
TABLE 3 AVERAGE SELLING PRICE TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY TREATMENT AND KEY PLAYER, 2023–2025 62
TABLE 4 AVERAGE SELLING PRICE TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY REGION, 2023–2025 63
TABLE 5 ROLE OF COMPANIES IN ECOSYSTEM 67
TABLE 6 PATENT ANALYSIS 71
TABLE 7 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 72
TABLE 8 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 73
TABLE 9 KEY CONFERENCES AND EVENTS, 2025–2026 73
TABLE 10 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 77
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 16 IMPACT OF PORTER’S FIVE FORCES ON PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 81
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
TOP FOUR PRODUCTS (%) 83
TABLE 18 KEY BUYING CRITERIA FOR TOP FOUR PRODUCTS 83
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 87
TABLE 20 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 91
TABLE 21 KEY PRODUCTS IN SYNTHETIC MESH MARKET 92
TABLE 22 SYNTHETIC MESH SALES, BY COUNTRY, 2023–2030 (UNITS) 92
TABLE 23 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY REGION, 2023–2030 (USD MILLION) 93
TABLE 24 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 93
TABLE 25 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 94
TABLE 26 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 94
TABLE 27 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 95
TABLE 28 KEY PRODUCTS IN BIOLOGICAL GRAFTS MARKET 96
TABLE 29 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY REGION, 2023–2030 (USD MILLION) 96
TABLE 30 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 96
TABLE 31 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 97
TABLE 32 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 97
TABLE 33 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 98
TABLE 34 KEY PRODUCTS IN SUTURES MARKET 98
TABLE 35 SUTURE SALES, BY COUNTRY, 2023–2030 (UNITS) 99
TABLE 36 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 37 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 38 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 39 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 40 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 41 KEY PRODUCTS IN VAGINAL PESSARIES MARKET 102
TABLE 42 VAGINAL PESSARY SALES, BY COUNTRY, 2023–2030 (UNITS) 103
TABLE 43 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 44 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 45 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 46 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 47 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 48 KEY PRODUCTS IN PELVIC FLOOR THERAPY DEVICES MARKET 106
TABLE 49 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 50 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 51 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 52 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 53 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 54 KEY PRODUCTS IN ROBOTIC SURGERY SYSTEMS MARKET 109
TABLE 55 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 56 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 57 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 58 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 59 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 60 KEY PRODUCTS IN DIAGNOSTIC & ASSESSMENT TOOLS MARKET 113
TABLE 61 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 62 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 63 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 64 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 65 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 66 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 117
TABLE 67 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY TYPE, 2023–2030 (USD MILLION) 118
TABLE 68 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 69 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 70 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 71 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 72 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 73 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 74 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 75 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 76 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 77 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 78 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 79 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 80 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 81 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 82 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 83 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 84 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 85 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 86 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 87 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 88 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 89 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 90 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 91 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 92 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 93 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY REGION,
2023–2030 (USD MILLION) 133
TABLE 94 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 95 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 96 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 97 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION,
BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 98 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR
NON-SURGICAL, BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 99 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR
NON-SURGICAL, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 100 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 101 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 102 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 103 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 104 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 139
TABLE 105 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 106 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 107 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 108 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 109 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 110 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 111 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 112 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 113 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 114 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 146
TABLE 115 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 116 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 117 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 118 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 119 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 120 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 121 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 122 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 123 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 124 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 125 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY REGION, 2023–2030 (USD MILLION) 153
TABLE 126 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 127 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 128 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 129 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 130 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY REGION, 2023–2030 (USD MILLION) 156
TABLE 131 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 132 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 133 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 134 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2022–2030 (USD MILLION) 158
TABLE 135 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 136 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 137 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 138 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 139 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 140 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 163
TABLE 141 HOSPITALS PER CAPITA, BY COUNTRY, 2024 164
TABLE 142 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 143 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 144 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 145 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 146 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 147 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 148 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 149 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 150 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 151 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 152 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 153 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 171
TABLE 154 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 155 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 172
TABLE 156 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 157 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 174
TABLE 158 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 159 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 160 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 161 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 176
TABLE 162 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY REGION, 2023–2030 (USD MILLION) 178
TABLE 163 NORTH AMERICA: MACROECONOMIC INDICATORS 179
TABLE 164 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 165 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 181
TABLE 166 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 182
TABLE 167 NORTH AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 168 NORTH AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 169 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 183
TABLE 170 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 184
TABLE 171 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 185
TABLE 172 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 185
TABLE 173 US: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 174 US: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 175 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 176 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 187
TABLE 177 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 188
TABLE 178 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 189
TABLE 179 CANADA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 180 CANADA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 181 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190
TABLE 182 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 191
TABLE 183 EUROPE: MACROECONOMIC INDICATORS 192
TABLE 184 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 185 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 193
TABLE 186 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 193
TABLE 187 EUROPE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 188 EUROPE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 189 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195
TABLE 190 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 191 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 196
TABLE 192 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 197
TABLE 193 GERMANY: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 194 GERMANY: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 195 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198
TABLE 196 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 199
TABLE 197 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 200
TABLE 198 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 200
TABLE 199 FRANCE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 200 FRANCE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 201 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 202
TABLE 202 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 202
TABLE 203 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 204
TABLE 204 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 204
TABLE 205 UK: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 206 UK: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 207 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 206
TABLE 208 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 206
TABLE 209 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 208
TABLE 210 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 208
TABLE 211 ITALY: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 212 ITALY: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 209
TABLE 213 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 210
TABLE 214 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 210
TABLE 215 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 211
TABLE 216 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 212
TABLE 217 SPAIN: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 212
TABLE 218 SPAIN: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 213
TABLE 219 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 213
TABLE 220 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 214
TABLE 221 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 215
TABLE 222 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 215
TABLE 223 REST OF EUROPE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 224 REST OF EUROPE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 225 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217
TABLE 226 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 217
TABLE 227 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 219
TABLE 228 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 220
TABLE 229 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 220
TABLE 230 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 221
TABLE 231 ASIA PACIFIC: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 221
TABLE 232 ASIA PACIFIC: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 233 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 234 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 223
TABLE 235 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 224
TABLE 236 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 224
TABLE 237 CHINA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 238 CHINA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 239 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 226
TABLE 240 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 226
TABLE 241 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 228
TABLE 242 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 228
TABLE 243 JAPAN: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 244 JAPAN: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 245 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 230
TABLE 246 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 230
TABLE 247 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 232
TABLE 248 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 232
TABLE 249 INDIA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 250 INDIA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 251 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 234
TABLE 252 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 234
TABLE 253 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 236
TABLE 254 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 236
TABLE 255 AUSTRALIA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 256 AUSTRALIA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 257 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238
TABLE 258 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 238
TABLE 259 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 239
TABLE 260 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 240
TABLE 261 SOUTH KOREA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 262 SOUTH KOREA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 263 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 241
TABLE 264 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 242
TABLE 265 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 243
TABLE 266 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 243
TABLE 267 REST OF ASIA PACIFIC: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 268 REST OF ASIA PACIFIC: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 269 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 245
TABLE 270 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 245
TABLE 271 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 246
TABLE 272 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 247
TABLE 273 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 247
TABLE 274 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 248
TABLE 275 LATIN AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 276 LATIN AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 277 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249
TABLE 278 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 250
TABLE 279 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 251
TABLE 280 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2023–2030 (USD MILLION) 251
TABLE 281 BRAZIL: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 282 BRAZIL: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 283 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 253
TABLE 284 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2023–2030 (USD MILLION) 253
TABLE 285 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 254
TABLE 286 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 255
TABLE 287 MEXICO: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 288 MEXICO: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 289 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256
TABLE 290 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 257
TABLE 291 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 258
TABLE 292 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 258
TABLE 293 REST OF LATIN AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 294 REST OF LATIN AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 295 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260
TABLE 296 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 260
TABLE 297 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 261
TABLE 298 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 262
TABLE 299 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 262
TABLE 300 MIDDLE EAST & AFRICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 301 MIDDLE EAST & AFRICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 302 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264
TABLE 303 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 264
TABLE 304 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 266
TABLE 305 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET:
DEGREE OF COMPETITION 268
TABLE 306 REGION FOOTPRINT 272
TABLE 307 PRODUCT FOOTPRINT 273
TABLE 308 TREATMENT FOOTPRINT 274
TABLE 309 APPLICATION FOOTPRINT 274
TABLE 310 LIST OF START-UPS/SMES 277
TABLE 311 COMPETITIVE BENCHMARKING OF START-UPS/SMES 278
TABLE 312 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET:
PRODUCT LAUNCHES/APPROVALS, 2022–2025 281
TABLE 313 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET:
DEALS, 2022–2025 282
TABLE 314 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET:
OTHER DEVELOPMENTS, 2022–2025 283
TABLE 315 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 284
TABLE 316 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 285
TABLE 317 BOSTON SCIENTIFIC CORPORATION: DEALS 286
TABLE 318 COLOPLAST GROUP: COMPANY OVERVIEW 287
TABLE 319 COLOPLAST GROUP: PRODUCTS OFFERED 289
TABLE 320 INTUITIVE SURGICAL OPERATIONS, INC.: COMPANY OVERVIEW 290
TABLE 321 INTUITIVE SURGICAL OPERATIONS, INC.: PRODUCTS OFFERED 291
TABLE 322 INTUITIVE SURGICAL OPERATIONS, INC.: PRODUCT LAUNCHES/APPROVALS 292
TABLE 323 COOPERCOMPANIES: COMPANY OVERVIEW 293
TABLE 324 COOPERCOMPANIES: PRODUCTS OFFERED 294
TABLE 325 COOPERCOMPANIES: DEALS 295
TABLE 326 JOHNSON & JOHNSON: COMPANY OVERVIEW 296
TABLE 327 JOHNSON & JOHNSON: PRODUCTS OFFERED 297
TABLE 328 JOHNSON & JOHNSON: PRODUCT LAUNCHES/APPROVALS 298
TABLE 329 JOHNSON & JOHNSON: DEALS 298
TABLE 330 JOHNSON & JOHNSON: OTHER DEVELOPMENTS 298
TABLE 331 GE HEALTHCARE: COMPANY OVERVIEW 300
TABLE 332 GE HEALTHCARE: PRODUCTS OFFERED 301
TABLE 333 GE HEALTHCARE: PRODUCT LAUNCHES/APPROVALS 302
TABLE 334 GE HEALTHCARE: DEALS 302
TABLE 335 GE HEALTHCARE: OTHER DEVELOPMENTS 302
TABLE 336 INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW 303
TABLE 337 INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED 304
TABLE 338 B. BRAUN SE: COMPANY OVERVIEW 305
TABLE 339 B. BRAUN SE: PRODUCTS OFFERED 306
TABLE 340 B. BRAUN SE: DEALS 307
TABLE 341 PFM MEDICAL GMBH: COMPANY OVERVIEW 308
TABLE 342 PFM MEDICAL GMBH: PRODUCTS OFFERED 308
TABLE 343 CALDERA MEDICAL: COMPANY OVERVIEW 309
TABLE 344 CALDERA MEDICAL: PRODUCTS OFFERED 309
TABLE 345 CALDERA MEDICAL: DEALS 310
LIST OF FIGURES
FIGURE 1 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SEGMENTATION 31
FIGURE 2 RESEARCH DESIGN 34
FIGURE 3 TOP-DOWN APPROACH 41
FIGURE 4 DATA TRIANGULATION 42
FIGURE 5 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY PRODUCT, 2025 VS. 2030 (USD MILLION) 45
FIGURE 6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY TREATMENT, 2025 VS. 2030 (USD MILLION) 46
FIGURE 7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY APPLICATION, 2025 VS. 2030 (USD MILLION) 47
FIGURE 8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET,
BY END USER, 2025 VS. 2030 (USD MILLION) 48
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 49
FIGURE 10 RISE IN FEMALE GERIATRIC POPULATION TO DRIVE MARKET 51
FIGURE 11 HOSPITALS AND CHINA ACCOUNTED FOR SIGNIFICANT SHARES IN 2024 52
FIGURE 12 ASIA PACIFIC TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD 53
FIGURE 13 INDIA TO BE FASTEST-GROWING MARKET DURING FORECAST PERIOD 54
FIGURE 14 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET DYNAMICS 55
FIGURE 15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 61
FIGURE 16 VALUE CHAIN ANALYSIS 64
FIGURE 17 SUPPLY CHAIN ANALYSIS 65
FIGURE 18 ECOSYSTEM ANALYSIS 66
FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2020–2025 (USD MILLION) 67
FIGURE 20 PATENT ANALYSIS 70
FIGURE 21 PORTER’S FIVE FORCES ANALYSIS 80
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR PRODUCTS 82
FIGURE 23 KEY BUYING CRITERIA FOR TOP FOUR PRODUCTS 83
FIGURE 24 IMPACT OF AI ON PELVIC ORGAN PROLAPSE/PELVIC FLOOR
RECONSTRUCTION MARKET 85
FIGURE 25 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SNAPSHOT 180
FIGURE 26 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SNAPSHOT 219
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 267
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 268
FIGURE 29 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 271
FIGURE 30 COMPANY FOOTPRINT 272
FIGURE 31 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024 276
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK
BETA OF KEY VENDORS 279
FIGURE 33 EV/EBITDA OF KEY VENDORS 280
FIGURE 34 BRAND/PRODUCT COMPARATIVE ANALYSIS 280
FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 285
FIGURE 36 COLOPLAST GROUP: COMPANY SNAPSHOT 288
FIGURE 37 INTUITIVE SURGICAL OPERATIONS, INC.: COMPANY SNAPSHOT 291
FIGURE 38 COOPERCOMPANIES: COMPANY SNAPSHOT 294
FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT 297
FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT 301
FIGURE 41 INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT 304
FIGURE 42 B. BRAUN SE: COMPANY SNAPSHOT 306
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31
- 高純度ガス市場規模、シェア、動向、2030年までの世界予測 2025-10-30
- 動物用生物学的製剤市場規模、シェア、動向、2030年までの世界予測 2025-10-30
- エンジニアリング樹脂向け難燃剤市場規模、シェア、動向、2030年までの世界予測 2025-10-29
- アプリケーションモダナイゼーションサービス市場規模、シェア、動向、2031年までの世界予測 2025-10-29